Related Experiment Video
Updated: Aug 21, 2026
Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats
Published on: November 20, 2015
Exendin-4 improves neurodevelopmental outcome after neonatal germinal matrix hemorrhage
Andrea Jonsdotter1,2, Anna-Lena Leverin2, Pernilla Svedin3
1Department of Obstetrics and Gynecology, Region Västra Götaland, Sahlgrenska University Hospital, Gothenburg, Sweden.
Insights
Exendin-4 shows promise as a neuroprotective treatment for germinal matrix hemorrhage (GMH) in premature infants. This study found exendin-4 reduced brain injury and improved neurological outcomes in a rat model of GMH.
Area of Science:
- Neuroscience
- Neonatal Research
- Pharmacology
Background:
- Germinal matrix hemorrhage (GMH) is a frequent complication in premature infants, leading to significant neurodevelopmental impairment and mortality.
- Current treatments for GMH lack specific neuroprotective agents.
- Exendin-4, a drug for type 2 diabetes, has demonstrated neuroprotective properties in other neurological conditions.
Purpose of the Study:
- To investigate the potential neuroprotective effects of exendin-4 in a preterm rat model of GMH.
- To assess the impact of exendin-4 on acute brain injury markers and long-term neurodevelopmental outcomes following GMH.
Main Methods:
- Utilized a preterm postnatal day 5 rat model to induce GMH.
- Administered exendin-4 and saline to respective groups.
- Evaluated acute injury markers including microglial activation, caspase-3, p53, AIF-associated cell death, MMP-9, and neutrophil infiltration.
- Assessed neurodevelopmental outcomes using negative geotaxis, eye-opening latency, and rotarod tests.
- Quantified gray and white matter protection at various time points post-injury.
Main Results:
- Exendin-4 treatment significantly reduced markers of acute brain injury, including microglial activation, caspase-3 activation, p53 expression, and neutrophil infiltration.
- Exendin-4 administration improved neurodevelopmental outcomes, evidenced by better performance in negative geotaxis and faster eye-opening.
- Significant gray and white matter protection was observed as early as 48 hours, persisting up to 35 days post-GMH.
- Exendin-4-treated rats demonstrated notable recovery of motor function in the rotarod test.
Conclusions:
- Exendin-4 exerts significant short-term and long-term neuroprotective effects in a rat model of GMH.
- The findings suggest exendin-4 may be a potential therapeutic agent for reducing brain injury and improving neurological outcomes in premature infants with GMH.
Abstract:
Germinal matrix hemorrhage (GMH) is a common complication in premature infants and is associated with a high risk of neurodevelopmental impairment and mortality. Currently, there are no specific neuroprotective treatments available. Exendin-4 is a drug used for the treatment of type 2 diabetes mellitus, and it has shown neuroprotective effects in several neurological disorders including Alzheimer's and Parkinson's disease. In this study, we used the preterm postnatal day 5 rat model of GMH to evaluate whether exendin-4 exerts neuroprotective effects in this setting. Our results show that in the acute phase, exendin-4 reduced microglial activation, caspase-3 activation, p53 expression, AIF-associated cell death, MMP-9 expression, and neutrophil infiltration into the hemorrhage site. Exendin-4 treatment improved neurodevelopmental outcomes in both negative geotaxis and eye-opening latency when compared to saline-treated GMH controls, and conferred gray and white matter protection as early as 48 h after injury, with persistent neuroprotection observed at 5, 11, and 35 days after GMH. Exendin-4-treated animals also showed significant recovery of motor function in the rotarod test. In summary, this study demonstrates that exendin-4 reduces brain injury in a rat model of GMH in both the short and long term and is associated with improved neurological outcome.
